Company
Genmab
Genmab has 19 drugs tracked on RxWires: 5 in Phase 3, 2 in Phase 2, 4 in Phase 1/2, 8 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Rina-S | Phase 3 | Platinum-Sensitive Ovarian Cancer |
| Petosemtamab | Phase 3 | Left-sided Colorectal Cancer |
| Epcoritamab | Phase 3 | Diffuse Large B-Cell Lymphoma |
| Acasunlimab | Phase 3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC |
| Zalutumumab | Phase 3 | Head and Neck Cancer |
| Zanubrutinib | Phase 2 | Follicular Lymphoma |
| HuMax-CD4 | Phase 2 | Cutaneous T-Cell Lymphoma |
| Enapotamab vedotin (HuMax-AXL-ADC) | Phase 1/2 | Ovarian Cancer |
| GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells. | Phase 1/2 | Breast Cancer, Breast Neoplasms |
| rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone | Phase 1/2 | Diffuse Large B-Cell Lymphoma |
| GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4. | Phase 1/2 | Locally Advanced or Metastatic Solid Tumor(s) |
| Siltuximab | Phase 1 | Non-Hodgkin Lymphoma |
| GEN1042 | Phase 1 | Malignant Solid Tumor |
| GEN3018 | Phase 1 | R/R AML |
| GEN1057 | Phase 1 | Advanced Malignant Solid Tumors |
| GEN1056 | Phase 1 | Solid Tumor, Adult |
| GEN1106 | Phase 1 | Solid Tumors |
| GEN1079 | Phase 1 | Advanced Solid Tumors |
| Biopsy | Phase 1 | Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder |
Latest
Follow Genmab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.